Michael Wang, Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center, shared an article by Tycel Phillips, et al. on X:
“Our Phase 1b study in Haematologica shows that the triple combination of acalabrutinib, bendamustine, and rituximab (ABR) was effective in patients with treatment-naïve or relapsed/refractory MCL, with a similar toxicity profile as single agents.”
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Authors: Tycel Phillips, et al.
More posts featuring Michael Wang.